EUVIMED · CrossrefZeitschrift
Experimental Hematology & Oncology
ISSN 2162-3619 · Springer Science and Business Media LLC
Neueste Artikel
RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis
CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering
A non-IMiD multi-target degrader reactivates fetal hemoglobin
Subtype-resolved tumor-intrinsic programs in immune-cold breast cancer: mechanistic interactions, evidence gaps, and translational priorities
Dismantling the immune-metabolic barrier in TP53-mutant hematologic malignancies
Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms
Combined casein kinase II and MAPK signalling inhibition as a therapeutic strategy for metastatic colorectal cancer
SCGB3A2 marks a low-angiogenesis tumor cell state associated with extracellular PGK2 and angiostatin in lung adenocarcinoma
HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation
Timdarpacept (IMM01) combined with azacitidine (AZA) as first-line therapy in adults with higher risk chronic myelomonocytic leukemia (CMML): results from a prospective, multicenter, phase II study
Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation
Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design
Tumor-intrinsic NSUN2 orchestrates immunosuppression in lung adenocarcinoma via the m5C-HDAC8-CCL5 axis
Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer
Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy
Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies
Systematic and precise interventions for KRAS-mutant cancers
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherapy
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance
Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application
NAT10-mediated lipid metabolic reprogramming drives EGFR-TKI resistance in non-small cell lung cancer via ac4C-dependent mRNA stabilization
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies
Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming
Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer
EUVIMED